Evaluation of Silver Nanoparticles for the Prevention of COVID-19
- Conditions
- Coronavirus Disease 2019 (COVID-19)
- Interventions
- Device: Mouthwash and nose rinse with the AgNPs solutionDevice: Mouthwashes and nose rinse in a conventional way
- Registration Number
- NCT04894409
- Lead Sponsor
- Cluster de Bioeconomia de Baja California, A.C
- Brief Summary
In this research, silver nanoparticles (AgNPs) were tested in vitro and shown to have an inhibitory effect on SARS-CoV-2 infection in cultured cells. Subsequently, the investigators assessed the effects of mouthwash and nose rinse with ARGOVIT® silver nanoparticles (AgNPs), in the prevention of SARS-CoV-2 contagion in health workers consider as high-risk group of acquiring the infection in the General Tijuana Hospital, Mexico, a hospital for the exclusive recruitment of patients diagnosed with COVID-19.
- Detailed Description
SARS-CoV-2 infection in hospital areas is of a particular concern, since the close interaction between health care personnel and patients diagnosed with COVID-19, which allows virus to be easily spread between them and subsequently to their families and communities. Preventing SARS-CoV-2 infection among healthcare personnel is essential to reduce the frequency of infections and outbreaks during the pandemic. In a first step, silver nanoparticles (AgNPs) were tested in vitro to determine an inhibitory effect on SARS-CoV-2 infection in cultured cells. Subsequently, the investigators assess the effects of mouthwash and nose rinse with ARGOVIT® silver nanoparticles (AgNPs), in the prevention of SARS-CoV-2 contagion in health workers consider as high-risk group of acquiring the infection in the General Tijuana Hospital, Mexico, a hospital for the exclusive recruitment of patients diagnosed with COVID-19. The investigators present a prospective randomized study of 231 participants that was carried out for 9 weeks (during the declaration of a pandemic). The "experimental" group was instructed to do mouthwash and nose rinse with the AgNPs solution; the "control" group was instructed to do mouthwashes and nose rinse in a conventional way.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 231
- Men and women health workers in the General Tijuana Hospital, Mexico who works in high-risk areas with direct contact with patients infected and diagnosed with COVID-19.
- persons with history of hypersensitivity to silver (rashes and other contraindications),
- a history of SARS-CoV-2 infection in the three months prior to the start of the study, any respiratory distress,
- and refusal to sign the informed consent.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Experimental group Mouthwash and nose rinse with the AgNPs solution The experimental group was instructed to do mouthwash and nose rinse with the AgNPs solution. Control group Mouthwashes and nose rinse in a conventional way The "control" group was instructed to do mouthwashes and nose rinse in a conventional way.
- Primary Outcome Measures
Name Time Method Incidence of SARS-CoV-2 infection in the control group. 9 weeks Percentage of participants infected of SARS-CoV-2 in the control group.
Incidence of SARS-CoV-2 infection in the experimental group. 9 weeks Percentage of participants infected of SARS-CoV-2 in the experimental group.
- Secondary Outcome Measures
Name Time Method Number of participants with adverse reactions by AgNPs. 9 weeks Number of participants with adverse reactions by performing mouthwash and nose rinse with AgNPs.
Trial Locations
- Locations (1)
Tijuana General Hospital
🇲🇽Tijuana, Baja California, Mexico